Bristol Myers Squibb reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer remains bullish on the drugmaker, calling it a 'buy' and seeing the stock decline as an opportunity. The company's new schizophrenia treatment Cobenfy is a key driver of the positive outlook, with sales potential expected to grow significantly in the coming years.
Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer's faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts' estimates compiled by LSEG. Adjusted earnings per share of $1.67 in the three months ended Dec. 31 topped estimates of $1.46, LSEG data showed.
Boxes of Opdivo from Bristol Myers are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, July 22, 2022.on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer's faith in the drugmaker is unshaken.
Finance Healthcare BRISTOL MYERS SQUIBB EARNINGS STOCK GUIDANCE COBENFY SCHIZOPHRENIA DRUGS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bristol Myers Squibb CEO describes new drug for treating schizophreniaBristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar disorder and Alzheimer’s…
Read more »
Bristol Myers Squibb's Cobenfy: A New Hope for Schizophrenia TreatmentA revolutionary new drug, Cobenfy, developed by Bristol Myers Squibb, has been approved by the FDA to treat schizophrenia and other psychiatric disorders. Cobenfy offers significant benefits over traditional medications, providing comparable efficacy while minimizing serious side effects. The drug has garnered positive feedback from both patients and healthcare professionals, with preliminary results suggesting its ability to address a wider range of symptoms.
Read more »
CNBC Investing Club with Jim Cramer: Bristol Myers Squibb, DuPont Spinoff, and AI Chip DemandJim Cramer highlights Bristol Myers Squibb as a potential top stock for 2025, discussing the company's promising schizophrenia drug and other potential applications. DuPont accelerates its spinoff timeline, while Cramer expresses a preference for selling Honeywell shares. Taiwan Semiconductor Manufacturing's strong AI chip revenue projections benefit Club holdings Nvidia and Broadcom.
Read more »
Jim Cramer Boosts Bristol Myers Squibb Position, Sees Growth PotentialJim Cramer's Charitable Trust increases its stake in Bristol Myers Squibb, citing confidence in the company's growth prospects, particularly with its new schizophrenia treatment, Cobenfy. The Trust also discusses its rationale for maintaining a position in Coterra Energy despite a desire to trim holdings due to trading restrictions.
Read more »
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidanceThe company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face competition from cheaper generics.
Read more »
Bristol Myers Squibb Unveils Cost-Cutting Plans and Beats Q4 Earnings ExpectationsBristol Myers Squibb announced a $2 billion cost-reduction plan by 2027, aiming to bolster long-term growth. Despite issuing lower-than-expected 2025 revenue guidance due to generic competition, the company delivered strong fourth-quarter earnings and revenue, fueled by Eliquis and its growth portfolio.
Read more »